Newling DW - Search Results

1

A phase II study of epirubicin in advanced transitional cell bladder cancer. The Yorkshire Urological Cancer Research Group.

Jones WG, Sokal MP, Ostrowski MJ, Newling DW. Jones WG, et al. Among authors: newling dw. Clin Oncol (R Coll Radiol). 1993;5(1):25-9. doi: 10.1016/s0936-6555(05)80691-0. Clin Oncol (R Coll Radiol). 1993. PMID: 8424911 Clinical Trial.

2

Neoadjuvant chemotherapy in T3-4 N0-X M0 transitional cell carcinoma of the bladder. Problems of clinical and pathological evaluation of response.

Splinter TA, ten Kate FJ, Schröder FH, Denis L, Newling D, Jones WG, Jacqmin D, Boeken Kruger CG, Stoter G, de Voogt HJ, et al. Splinter TA, et al. Prog Clin Biol Res. 1988;269:579-90. Prog Clin Biol Res. 1988. PMID: 3393555 No abstract available.

3

Multi-centre phase II study of low dose intravesical epirubicin in the treatment of superficial bladder cancer. Yorkshire and Scottish Urological Cancer Research Groups.

Whelan P, Cumming JA, Garvie WH, Hargreave TB, Kirk D, Newling DW, Robinson MR, Smith PH. Whelan P, et al. Among authors: newling dw. Br J Urol. 1991 Jun;67(6):600-2. doi: 10.1111/j.1464-410x.1991.tb15223.x. Br J Urol. 1991. PMID: 2070204 Clinical Trial.

4

Update of EORTC clinical trials in prostate cancer. The EORTC Genito-Urinary Group.

Newling DW, Pavone Macaluse M, Smith P, de Voogt HJ, Robinson MR, Schroder FH, Denis L, Jones WG, de Pauw M, Sylvester R. Newling DW, et al. Semin Urol. 1992 Feb;10(1):65-71. Semin Urol. 1992. PMID: 1565905 Review. No abstract available.

5

A multi-centre phase two study of intravesical epirubicin in the treatment of superficial bladder tumour.

Cumming JA, Kirk D, Newling DW, Hargreave TB, Whelan P. Cumming JA, et al. Among authors: newling dw. Eur Urol. 1990;17(1):20-2. doi: 10.1159/000463992. Eur Urol. 1990. PMID: 2180719 Clinical Trial.

6

The chemotherapy of advanced bladder cancer.

Newling DW, Stoter G, Sylvester R, de Pauw M. Newling DW, et al. Cancer Chemother Pharmacol. 1987;20 Suppl:S39-43. doi: 10.1007/BF00262483. Cancer Chemother Pharmacol. 1987. PMID: 3664943

7

Vincristine in advanced bladder cancer: a European organization for research on treatment of cancer (EORTC) phase II study.

Richards B, Newling D, Fossa S, Bastable JR, Denis L, Jones WB, de Pauw M. Richards B, et al. Cancer Treat Rep. 1983 Jun;67(6):575-7. Cancer Treat Rep. 1983. PMID: 6861163

8

Mitomycin C versus estramustine in the treatment of hormone resistant metastatic prostate cancer: the final analysis of the European Organization for Research and Treatment of Cancer, genitourinary group prospective randomized phase III study (30865).

Newling DW, Fossa SD, Tunn UW, Kurth KH, de Pauw M, Sylvester R. Newling DW, et al. J Urol. 1993 Dec;150(6):1840-4. doi: 10.1016/s0022-5347(17)35911-6. J Urol. 1993. PMID: 8230517 Clinical Trial.

9

Quality of life in patients with muscle-infiltrating bladder cancer and hormone-resistant prostatic cancer.

Fosså SD, Aaronson N, Calais da Silva F, Denis L, Newling D, Hosbach G, Kaalhus O. Fosså SD, et al. Eur Urol. 1989;16(5):335-9. doi: 10.1159/000471611. Eur Urol. 1989. PMID: 2476317

10

A phase II study of intravesical mitomycin C in the treatment of superficial bladder cancer.

Harrison GS, Green DF, Newling DW, Richards B, Robinson MR, Smith PH. Harrison GS, et al. Among authors: newling dw. Br J Urol. 1983 Dec;55(6):676-9. doi: 10.1111/j.1464-410x.1983.tb03402.x. Br J Urol. 1983. PMID: 6418263

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

140 results

Search Page

Filters